Published in Am J Pathol on May 28, 2009
Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis. Am J Pathol (2011) 2.12
Cell-surface sensors for real-time probing of cellular environments. Nat Nanotechnol (2011) 1.28
Intravital microscopy as a tool to study drug delivery in preclinical studies. Adv Drug Deliv Rev (2010) 1.17
Human endothelial colony-forming cells serve as trophic mediators for mesenchymal stem cell engraftment via paracrine signaling. Proc Natl Acad Sci U S A (2014) 1.06
Pericyte-derived MFG-E8 regulates pathologic angiogenesis. Arterioscler Thromb Vasc Biol (2011) 1.01
Dual delivery of VEGF and MCP-1 to support endothelial cell transplantation for therapeutic vascularization. Biomaterials (2010) 0.99
Spontaneous nonthymic tumors in SCID mice. Comp Med (2011) 0.87
Developmental and tumoral vascularization is regulated by G protein-coupled receptor kinase 2. J Clin Invest (2013) 0.87
Dissecting the role of human embryonic stem cell-derived mesenchymal cells in human umbilical vein endothelial cell network stabilization in three-dimensional environments. Tissue Eng Part A (2012) 0.79
Pressuromodulation at the cell membrane as the basis for small molecule hormone and peptide regulation of cellular and nuclear function. J Transl Med (2015) 0.76
Horizontal alignment of 5' -> 3' intergene distance segment tropy with respect to the gene as the conserved basis for DNA transcription. Future Sci OA (2016) 0.75
Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev (2004) 16.52
Angiogenesis in life, disease and medicine. Nature (2005) 15.36
Molecular regulation of vessel maturation. Nat Med (2003) 11.74
Polymeric system for dual growth factor delivery. Nat Biotechnol (2001) 7.20
PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol (1998) 5.21
Macrophage polarization in tumour progression. Semin Cancer Biol (2008) 4.62
Tissue engineering: creation of long-lasting blood vessels. Nature (2004) 4.50
Unchain my heart: the scientific foundations of cardiac repair. J Clin Invest (2005) 4.25
Pericytes in the microvasculature. Cardiovasc Res (1996) 3.95
Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res (1994) 3.84
A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature (2008) 3.74
Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev (2003) 3.48
Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol (1998) 3.18
During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med (1996) 3.18
Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest (2000) 2.92
Engineering vascularized tissue. Nat Biotechnol (2005) 2.69
Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. Nat Biotechnol (2007) 2.65
Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc Res (2001) 2.55
Endothelium-specific ablation of PDGFB leads to pericyte loss and glomerular, cardiac and placental abnormalities. Development (2004) 2.44
Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev (2004) 2.39
Angiogenesis: where do we stand now? Circulation (2005) 2.08
Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J (2001) 1.86
Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res (2007) 1.70
Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J Clin Invest (2007) 1.47
Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells. J Biol Chem (2002) 1.46
What brings pericytes to tumor vessels? J Clin Invest (2003) 1.45
Vascular endothelial growth factor (VEGF) stimulates monocyte migration through endothelial monolayers via increased integrin expression. Eur J Cell Biol (2000) 1.10
Platelet factor 4/CXCL4-stimulated human monocytes induce apoptosis in endothelial cells by the release of oxygen radicals. J Leukoc Biol (2008) 1.05
Polarized secretion of a platelet-derived growth factor-like chemotactic factor by endothelial cells in vitro. J Cell Biol (1987) 0.99
Hyperhomocysteinemia impairs angiogenesis in response to hindlimb ischemia. Arterioscler Thromb Vasc Biol (2000) 0.97
Intracranial microenvironment reveals independent opposing functions of host alphaVbeta3 expression on glioma growth and angiogenesis. J Biol Chem (2006) 0.96
Platelet-derived growth factor B-chain of hematopoietic origin is not necessary for granulation tissue formation and its absence enhances vascularization. Am J Pathol (2001) 0.81
Endothelial progenitor cells transfected with PDGF: cellular and molecular targets for prevention of diabetic microangiopathy. Med Hypotheses (2006) 0.80
Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 13.36
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell (2004) 8.78
Photodynamic therapy for cancer. Nat Rev Cancer (2003) 8.00
Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol (2006) 7.19
Angiogenesis in brain tumours. Nat Rev Neurosci (2007) 6.82
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res (2004) 5.65
Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov (2011) 5.59
Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med (2003) 5.50
Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med (2009) 5.41
Lymphatic metastasis in the absence of functional intratumor lymphatics. Science (2002) 5.32
Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol (2002) 5.04
Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol (2012) 4.84
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
Tissue engineering: creation of long-lasting blood vessels. Nature (2004) 4.50
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer (2002) 3.96
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med (2009) 3.85
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol (2013) 3.81
Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res (2007) 3.64
Pathology: cancer cells compress intratumour vessels. Nature (2004) 3.60
Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res (2007) 3.45
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature (2002) 3.40
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39
Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A (2011) 3.34
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov (2011) 3.34
Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. Biophys J (2002) 3.25
Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat Med (2005) 3.19
Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood (2008) 3.13
The role of nitric oxide in tumour progression. Nat Rev Cancer (2006) 3.08
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol (2009) 3.02
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res (2009) 3.00
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res (2013) 2.98
Response criteria for glioma. Nat Clin Pract Oncol (2008) 2.69
Engineering vascularized tissue. Nat Biotechnol (2005) 2.69
Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem (2007) 2.67
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A (2012) 2.66
Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. Nat Biotechnol (2007) 2.65
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 2.64
Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels. Blood (2007) 2.64
Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A (2010) 2.62
A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc (2007) 2.59
Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol (2006) 2.58
Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation (2010) 2.53
Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res (2010) 2.50
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A (2012) 2.50
Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res (2006) 2.42
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res (2011) 2.40
CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res (2011) 2.39
Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res (2006) 2.35